ProCE Banner Activity

Phase I DREAMM-9 Study of Belantamab Mafodotin + VRd in ASCT-Ineligible Newly Diagnosed MM

Slideset Download
Conference Coverage
The safety profile of belantamab mafodotin plus VRd for patients with newly diagnosed MM who are not eligible for ASCT was similar to the known safety of single-agent belantamab mafodotin in patients with R/R MM.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation